Quarterly Report Summary 2007.01.01 - 2007.09.30 Actual report period 2007.07.01 – 2007.09.30

• Probi’s net sales for the period January to September amounted to 30,6 million SEK (20,3), an increase of 51 percent (-5). The net sales during the third quarter was 10,4 million SEK (6,9). Growth within the business area Functional Food was 40 percent (-8) during the period January to September and 117 percent (17) within the business area Dietary Supplements. Growth during the third quarter was 43 percent (-1) within Functional Food and 104 percent (0) within Dietary Supplements.

• After tax result for the period January to September continued to be positive and amounted to 4,8 million SEK (-5,1). Even the third quarter after tax result improved to 2,9 million SEK (-0,9).

• Earnings per share for the period January to September amounted to 0,51 SEK (-0,55) and to 0,31 SEK (-0,10) during the third quarter.

• Cash flow from current activities during the period January to September improved to 15,6 million SEK (-1,8). Liquid assets were 45,5 million SEK (36,7) at the end of the period.

• Probi has signed a license agreement with NextFoods for the US market. An assortment of “fruit shots” will be launched with significant market investments during fall 2008.

• Probi has carried out a placebo controlled study in which a combination of one the company’s patented Lactobacillus plantarum strains and a Lactobacillus paracasei have shown effect on the immune system and may thereby reduce the duration and severity of common cold infections.

• Institut Rosell has signed another agreement in India for the sale of dietary supplements. Ranbaxy Pharmaceuticals will launch the dietary supplement to gastro specialists during fall.

• After the end of the period, Probi’s partner Institut Rosell has started to supply the pharmaceutical company Merck in Chile with a dietary supplement product based on Probi’s bacteria Lp299v.

• Probi still deems that result and cash flow from current activities will be positive during 2007.